## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	Confirmation No. 6308
Ifor Delme BOWEN, et al.	)	Examiner: Q. MI
Serial No. 10/579,135	)	Group Art Unit: 1655
Filed: April 11, 2007	)	Atty. Dkt. No. 000487.00042
For: Anti-Tumor Terpene Compounds	)	

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents c/o Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In response to the Office Action mailed February 24, 2009, Applicants elect for prosecution in this application Group I, drawn to a method of treating or preventing cancer comprising administering to a patent in need of a terpene or oxygenated derivative thereof, and the terpene is selected from the group consisting of trans-beta-ocimene and gamma-bisabolene. This Group encompasses claims 2-5, 8, and 11.

Applicants further elect gamma-bisabolene as the specific compound and leukemia as the specific type of cancer.

No additional fee is believed due in connection with this response. However, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: March 19, 2009 By: <u>/Sarah A. Kagan/</u>
Sarah A. Kagan
Registration No. 32,141

Banner & Witcoff, Ltd. Customer No. 22907